Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis

AIM: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a meta-analysis to compare the two regimens. METHOD: Articles wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchetti, Claudia, De Felice, Francesca, Musella, Angela, Palaia, Innocenza, Monti, Marco, Musio, Daniela, Muzii, Ludovico, Tombolini, Vincenzo, Panici, Pierluigi Benedetti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295464/
https://www.ncbi.nlm.nih.gov/pubmed/27509061
http://dx.doi.org/10.18632/oncotarget.11094
Descripción
Sumario:AIM: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a meta-analysis to compare the two regimens. METHOD: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. RESULTS: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77-1.16, p=0.06), as well as in term of severe acute toxicity. CONCLUSION: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.

Ejemplares similares